ID2 and neoplasm: While the low mutation-related neoantigen in ID2- positive LUADs could lead to poor immune recognition and may limit the clinical efficacy of currently available immune checkpoint inhibitors, the enrichment of Helper T Cells in the tumor microenvironment suggests that novel immunotherapies harnessing these existing T cell subsets could represent a more effective strategy.